Skip to main content
SpringerLink
Log in

Induktionschemotherapie bei hepatozellulären Karzinomen

  • Chapter
Regionale Therapie maligner Tumoren

  • 1146 Accesses

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) ist die weltweit fünfthäufigste Krebsart und die vierthäufigste Ursache krebsbedingter Todesfälle [1]. Die Inzidenz von Leberzellkarzinomen unterliegt geographischen Schwankungen, wobei die Mehrzahl der Fälle in Entwicklungsländern – insbesondere in Asien und Afrika – zu verzeichnen ist, aufgrund der hohen Prävalenz von Hepatitis-B-Virus-Infektionen (HBV-Infektionen) in diesen Endemiegebieten. In den westlichen Ländern einschließlich Nordamerika [2], Europa [3] und Japan ist hingegen eine Zunahme der HCC-Fälle infolge von Hepatitis-CVirus- Infektionen (HCV-Infektionen) und alkoholischer Leberzirrhose zu beobachten. Die Inzidenz von Leberzellkarzinomen nimmt aufgrund einer zunehmenden Prävalenz nicht alkoholischer Steatohepatitis infolge von Adipositas sowie des metabolischen Syndroms fortlaufend zu [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74–108.

    Article  PubMed  Google Scholar 

  2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340(10):745–50.

    Article  PubMed  CAS  Google Scholar 

  3. Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 2008; 48(1):137–45.

    Article  PubMed  Google Scholar 

  4. Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1):S97–103.

    Article  PubMed  CAS  Google Scholar 

  5. Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229(3):322–30.

    Article  PubMed  CAS  Google Scholar 

  6. Nagasue N, Kohno H, Chang YC, et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993; 217(4):375–84.

    Article  PubMed  CAS  Google Scholar 

  7. Tanaka H, Kubo S, Tsukamoto T, et al. Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria. Transplant Proc 2005; 37(2):1254–6.

    Article  PubMed  CAS  Google Scholar 

  8. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 2007; 26(33):4877–81.

    Article  PubMed  CAS  Google Scholar 

  9. Chan KT, Lung ML. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 2004; 53(6):519–26.

    Article  PubMed  CAS  Google Scholar 

  10. Fabregat I, Roncero C, Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 2007; 27(2):155–62.

    Article  PubMed  CAS  Google Scholar 

  11. Okada Y, Tosaka A, Nimura Y, et al. Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene 2001; 272(1–2):141–8.

    Google Scholar 

  12. Watanuki A, Ohwada S, Fukusato T, et al. Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. Anticancer Res 2002; 22(2B):1113–9.

    PubMed  CAS  Google Scholar 

  13. Zhu H, Chen XP, Luo SF, et al. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 2005; 24(4):565–74.

    PubMed  CAS  Google Scholar 

  14. Hong RL, Tseng YL. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003; 51(5):433–8.

    Google Scholar 

  15. Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54(5): 385–90.

    Article  PubMed  CAS  Google Scholar 

  16. Lai EC, Choi TK, Cheng CH, et al. Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 1990; 66(8):1685–7.

    Article  PubMed  CAS  Google Scholar 

  17. Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25(21):3069–75.

    Article  PubMed  CAS  Google Scholar 

  18. Pohl J, Zuna I, Stremmel W, et al. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001; 47(5):359–65.

    Article  PubMed  CAS  Google Scholar 

  19. Okada S, Okazaki N, Nose H, et al. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993; 50(1):22–6.

    Article  Google Scholar 

  20. Ravry MJ, Omura GA, Bartolucci AA, et al. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70(2):311–2.

    Google Scholar 

  21. Falkson G, Ryan LM, Johnson LA, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987; 60(9):2141–5.

    Article  PubMed  CAS  Google Scholar 

  22. Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha- interferon in hepatocellular carcinoma. Am J Clin Oncol 1996; 19(2):136–9.

    Article  Google Scholar 

  23. Shiu W, Mok SD, Leung N, et al. Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma. Jpn J Clin Oncol 1987; 17(2):113–5.

    Google Scholar 

  24. Davis RB, Van Echo DA, Leone LA, et al. Phase II trial of mitoxantrone in advanced primary liver cancer: a Cancer and Leukemia Group B Study. Cancer Treat Rep 1986; 70(9):1125–6.

    PubMed  CAS  Google Scholar 

  25. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11(7):790–800.

    Article  PubMed  CAS  Google Scholar 

  26. Yang TS, Lin YC, Chen JS, et al. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89(4):750–6.

    Article  Google Scholar 

  27. Fuchs CS, Clark JW, Ryan DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002; 94(12):3186–91.

    Article  PubMed  CAS  Google Scholar 

  28. Guan Z, Wang Y, Maoleekoonpairoj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 2003; 89(10):1865–9.

    Article  PubMed  CAS  Google Scholar 

  29. O'Reilly EM, Stuart KE, Sanz-Altamira PM, et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001; 91(1):101–5.

    Article  Google Scholar 

  30. Porta C, Moroni M, Nastasi G, et al. 5-Fluorouracil and d,lleucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study. Oncology 1995; 52(6):487–91.

    Article  PubMed  CAS  Google Scholar 

  31. Baker LH, Saiki JH, Jones SE, et al. Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study. Cancer Treat Rep 1977; 61(8):1595–7.

    PubMed  CAS  Google Scholar 

  32. Bobbio-Pallavicini E, Porta C, Moroni M, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer 1997; 33(11):1784–8.

    Article  PubMed  CAS  Google Scholar 

  33. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5(7):1676–81.

    PubMed  CAS  Google Scholar 

  34. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97(20):1532–8.

    Article  PubMed  CAS  Google Scholar 

  35. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109(7):1384–90.

    Article  PubMed  CAS  Google Scholar 

  36. Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007; 97(7):862–7.

    Google Scholar 

  37. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51(4):459–62.

    Article  PubMed  CAS  Google Scholar 

  38. Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs 2004; 13(12):1555–68.

    Article  PubMed  CAS  Google Scholar 

  39. Jiang SY, Shyu RY, Yeh MY, et al. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 1995; 23(6):712–9.

    Article  Google Scholar 

  40. Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 2005; 23(19):4338–46.

    Article  PubMed  CAS  Google Scholar 

  41. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002; 36(5):1221–6.

    Article  PubMed  CAS  Google Scholar 

  42. Manesis EK, Giannoulis G, Zoumboulis P, et al. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995; 21(6):1535–42.

    PubMed  CAS  Google Scholar 

  43. Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998; 16(2):411–7.

    Google Scholar 

  44. Verhoef C, van Dekken H, Hofland LJ, et al. Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics. Dig Surg 2008; 25(1):21–6.

    Article  Google Scholar 

  45. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42(3):442–7.

    Article  Google Scholar 

  46. Becker G, Allgaier HP, Olschewski M, et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45(1):9–15.

    Article  PubMed  CAS  Google Scholar 

  47. Somers GF. Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol Chemother 1960; 15:111–6.

    Article  Google Scholar 

  48. Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103(1):119–25.

    Article  PubMed  CAS  Google Scholar 

  49. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005; 103(4):749–55.

    Article  PubMed  CAS  Google Scholar 

  50. Zhu AX, Fuchs CS, Clark JW, et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 2005; 10(6):392–8.

    Article  Google Scholar 

  51. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17(3):389–94.

    Article  PubMed  CAS  Google Scholar 

  52. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31(1):54–8.

    Article  Google Scholar 

  53. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64(19):7099–109.

    Article  PubMed  CAS  Google Scholar 

  54. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1):25–34.

    Article  PubMed  CAS  Google Scholar 

  55. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27(18):3027–35.

    Article  PubMed  CAS  Google Scholar 

  56. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110(5):1059–67.

    Article  PubMed  CAS  Google Scholar 

  57. Raoul JL FR, Kang YK, et al. Phase 2 study of first- and second- line treatment with brivanib in patients with hepatocellular carcinoma. ILCA Third Annual Conference, Milan, September 4–6, 2009, abstr O-030. 2009.

    Google Scholar 

  58. Toh H CP, Carr BI, Knox JJ, Gill S, Steinberg J, Carlson DM, Qian J, Qin Q, Yong W. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis [abstract]. J Clin Oncol 2009; 27 (15s): A4581.

    Google Scholar 

  59. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32(6):1224–9.

    Article  PubMed  CAS  Google Scholar 

  60. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27(6):1578–83.

    Article  PubMed  CAS  Google Scholar 

  61. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995; 332(19):1256–61.

    Google Scholar 

  62. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319): 1734–9.

    Article  PubMed  Google Scholar 

  63. Lin DY, Liaw YF, Lee TY, et al. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma- -a randomized controlled trial. Gastroenterology 1988; 94(2):453–6.

    Google Scholar 

  64. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11(2):181–4.

    Article  Google Scholar 

  65. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29(1):129–34.

    Article  PubMed  CAS  Google Scholar 

  66. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5): 1164–71.

    Article  PubMed  CAS  Google Scholar 

  67. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224(1):47–54.

    Article  PubMed  Google Scholar 

  68. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37(2): 429–42.

    Article  PubMed  CAS  Google Scholar 

  69. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30(1):6–25.

    Article  PubMed  Google Scholar 

  70. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46(3):474–81.

    Article  PubMed  CAS  Google Scholar 

  71. Ku Y, Saitoh M, Nishiyama H, et al. [Extracorporeal adriamycin- removal following hepatic artery infusion: use of direct hemoperfusion combined with veno-venous bypass]. Nippon Geka Gakkai Zasshi 1989; 90(10):1758–64.

    PubMed  CAS  Google Scholar 

  72. Ku Y, Saitoh M, Nishiyama H, et al. Extracorporeal removal of anticancer drugs in hepatic artery infusion: the effect of direct hemoperfusion combined with venovenous bypass. Surgery 1990; 107(3):273–81.

    PubMed  CAS  Google Scholar 

  73. Maekawa Y, Ku Y, Saitoh Y. Extracorporeal cisplatin removal using direct hemoperfusion under hepatic venous isolation for hepatic arterial chemotherapy: an experimental study on pharmacokinetics. Surg Today 1993; 23(1):58–62.

    Article  PubMed  CAS  Google Scholar 

  74. Kusunoki N, Ku Y, Tominaga M, et al. Effect of sodium thiosulfate on cisplatin removal with complete hepatic venous isolation and extracorporeal charcoal hemoperfusion: a pharmacokinetic evaluation. Ann Surg Oncol 2001; 8(5):449–57.

    Article  PubMed  CAS  Google Scholar 

  75. Curley SA, Byrd DR, Newman RA, et al. Hepatic arterial infusion chemotherapy with complete hepatic venous isolation and extracorporeal chemofiltration: a feasibility study of a novel system. Anticancer Drugs 1991; 2(2):175–83.

    Article  PubMed  CAS  Google Scholar 

  76. Beheshti MV, Denny DF, Jr., Glickman MG, et al. Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. J Vasc Interv Radiol 1992; 3(3):453–8.

    Article  Google Scholar 

  77. August DA, Verma N, Vaerten MA, et al. Pharmacokinetic evaluation of percutaneous hepatic venous isolation for administration of regional chemotherapy. Surg Oncol 1995; 4(4):205–16.

    Article  PubMed  CAS  Google Scholar 

  78. Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005; 23(15):3465–74.

    Article  PubMed  CAS  Google Scholar 

  79. Ku Y, Iwasaki T, Fukumoto T, et al. Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion. Ann Surg 1998; 227(4):519–26.

    Article  PubMed  CAS  Google Scholar 

  80. Curley SA, Newman RA, Dougherty TB, et al. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1994; 1(5):389–99.

    Article  PubMed  CAS  Google Scholar 

  81. Ku Y, Iwasaki T, Tominaga M, et al. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma. Ann Surg 2004; 239(1):53–60.

    Article  PubMed  Google Scholar 

  82. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983; 51(2):206–10.

    Article  PubMed  CAS  Google Scholar 

  83. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984; 68(3):487–91.

    PubMed  CAS  Google Scholar 

  84. Colombo M, Tommasini MA, Del Ninno E, et al. Hepatocellular carcinoma in Italy: report of a clinical trial with intravenous doxorubicin. Liver 1985; 5(6):336–41.

    PubMed  CAS  Google Scholar 

  85. Lai CL, Wu PC, Chan GC, et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62(3):479–83.

    Article  PubMed  CAS  Google Scholar 

  86. Mok TS, Leung TW, Lee SD, et al. A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 44(4):307–11.

    Article  PubMed  CAS  Google Scholar 

  87. Halm U, Etzrodt G, Schiefke I, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000; 11(1): 113–4.

    Article  Google Scholar 

  88. Wall JG, Benedetti JK, O'Rourke MA, et al. Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs 1997; 15(3):257–60.

    Article  PubMed  CAS  Google Scholar 

  89. Ravry MJ, Omura GA, Bartolucci AA. Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group trial. Cancer Treat Rep 1984; 68(12):1517–8.

    PubMed  CAS  Google Scholar 

  90. al-Idrissi HY. Combined 5-fluorouracil, adriamycin and mitomycin C in the management of adenocarcinoma metastasizing to the liver from an unknown primary site. J Int Med Res 1990; 18(5):425–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, 650-0017, Kobe, Japan

    Takumi Fukumoto MD, PhD & Yonson Ku MD, PhD

Authors
  1. Takumi Fukumoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yonson Ku MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medias Klinikum Burghausen, Burghausen

    Karl Reinhard Aigner

  2. University of Sydney, Sydney, Australia

    Frederick O. Stephens

  3. Universitätsklinikum Frankfurt, Frankfurt

    Thomas J. Vogl

  4. Universitätsklinikum Gießen, Gießen

    Winfried Padberg

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fukumoto, T., Ku, Y. (2013). Induktionschemotherapie bei hepatozellulären Karzinomen. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35014-6_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35013-9

  • Online ISBN: 978-3-642-35014-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation